Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H31O2.Na |
| Molecular Weight | 350.4701 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 6 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC([O-])=O
InChI
InChIKey=SNNDEWVSGZRIFE-FPYKSTABSA-M
InChI=1S/C22H32O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24;/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24);/q;+1/p-1/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-;
DescriptionCurator's Comment: description was created based on several sources, including
https://www.hsph.harvard.edu/nutritionsource/omega-3-fats/ |
https://www.ncbi.nlm.nih.gov/pubmed/24352849 |
https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm
Curator's Comment: description was created based on several sources, including
https://www.hsph.harvard.edu/nutritionsource/omega-3-fats/ |
https://www.ncbi.nlm.nih.gov/pubmed/24352849 |
https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm
Doconexent (Docosahexaenoic acid, DHA) is an omega-3 fatty acid that is a primary structural component of the human brain, cerebral cortex, skin, and retina. DHA is widely used as a food supplement, and is beleived to support healthy brain development in young childred, prevent cardiovascular disease and cognitive decline during Alzheimer's disease. Most of these claims, however, were not supported by clinical trials. DHA spray is used as a tanner.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095229 |
|||
Target ID: map04064 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of novel brain lipoxygenase products formed from docosahexaenoic acid (22:6w3). | 1988 |
|
| Hydrolysis of phosphatidylethanolamine by human pancreatic phospholipase A2. Effect of bile salts. | 1994 Feb |
|
| Nutrition and cognitive function. | 1997 Apr |
|
| Human plasma albumin transports [13C]docosahexaenoic acid in two lipid forms to blood cells. | 1997 Aug |
|
| Differential distribution and metabolism of arachidonic acid and docosahexaenoic acid by human placental choriocarcinoma (BeWo) cells. | 1998 Aug |
|
| Low plasma levels of docosahexaenoic acid in patients with liver cirrhosis and its correction with a polyunsaturated fatty acid-enriched soft oil capsule. | 1999 Apr |
|
| Peroxisome proliferator-activated receptors: nuclear control of metabolism. | 1999 Oct |
|
| Is there a relation between docosahexaenoic acid concentration in mothers' milk and visual development in term infants? | 2001 Mar |
|
| Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. | 2003 Jan |
|
| Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. | 2003 Mar 13 |
|
| The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. | 2003 Mar 28 |
|
| Omega-3 status and cerebrospinal fluid corticotrophin releasing hormone in perpetrators of domestic violence. | 2004 Dec 1 |
|
| Effects of hyperglycemia and hypercapnia on lipid metabolism during complete brain ischemia. | 2004 Dec 24 |
|
| Protective effects of dietary enrichment with docosahexaenoic acid plus protein in 5-fluorouracil-induced intestinal injury in the rat. | 2004 May |
|
| Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. | 2005 Jan |
|
| Differential modulation of the glutamate transporters GLT1, GLAST and EAAC1 by docosahexaenoic acid. | 2005 Mar 10 |
|
| Safety of docosahexaenoic acid (DHA) administered as DHA ethyl ester in a 9-month toxicity study in dogs. | 2016 Jun |
|
| Kinetics of docosahexaenoic acid ethyl ester accumulation in dog plasma and brain. | 2016 Oct |
|
| Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance. | 2017 Mar |
|
| [Separation of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester by simulated moving bed chromatography]. | 2018 Sep 8 |
Patents
Sample Use Guides
Doconexent is administered with food or as an oral supplement, or topically with food.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
81926-93-4
Created by
admin on Fri Dec 15 18:32:27 GMT 2023 , Edited by admin on Fri Dec 15 18:32:27 GMT 2023
|
PRIMARY | |||
|
71587300
Created by
admin on Fri Dec 15 18:32:27 GMT 2023 , Edited by admin on Fri Dec 15 18:32:27 GMT 2023
|
PRIMARY | |||
|
DBSALT002309
Created by
admin on Fri Dec 15 18:32:27 GMT 2023 , Edited by admin on Fri Dec 15 18:32:27 GMT 2023
|
PRIMARY | |||
|
295P7EPT4C
Created by
admin on Fri Dec 15 18:32:27 GMT 2023 , Edited by admin on Fri Dec 15 18:32:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
